ASCO 2021: First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer: Response and Survival Results Up to Five Years From the KEYNOTE-052 Phase 2 Study

(UroToday.com) Pembrolizumab was approved for cisplatin-ineligible patients with untreated advanced urothelial carcinoma based on initial results of the phase 2 KEYNOTE-052 study, which showed an objective response rate of 24%.¹ Updated results after two years of follow-up were consistent, showing an objective response rate of 29%.² At the 2021 ASCO annual meeting, Dr. Peter O’Donnell and collaborators presented updated results of the KEYNOTE-052 trial after up to 5 years of follow-up.